VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate.

[1]  J. Wess,et al.  Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154 , 2018, Neuropharmacology.

[2]  J. Wess,et al.  Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor , 2017, Neuron.

[3]  Bruce J. Melancon,et al.  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. , 2017, Bioorganic & medicinal chemistry letters.

[4]  Bruce J. Melancon,et al.  Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. , 2017, Bioorganic & medicinal chemistry letters.

[5]  Andrew S. Felts,et al.  Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation , 2017, Journal of medicinal chemistry.

[6]  N. Brandon,et al.  Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. , 2017, ACS medicinal chemistry letters.

[7]  Bruce J. Melancon,et al.  Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. , 2017, Bioorganic & medicinal chemistry letters.

[8]  N. Brandon,et al.  Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. , 2016, Bioorganic & medicinal chemistry letters.

[9]  Alison R. Gregro,et al.  Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. , 2016, Bioorganic & medicinal chemistry letters.

[10]  N. Brandon,et al.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects , 2016, Neuropharmacology.

[11]  P. Sexton,et al.  Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004. , 2015, ACS Chemical Neuroscience.

[12]  Bruce J. Melancon,et al.  Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents , 2014, ACS chemical neuroscience.

[13]  Anna L. Blobaum,et al.  Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. , 2012, Bioorganic & medicinal chemistry letters.

[14]  J. P. Kennedy,et al.  Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor , 2009, ChemMedChem.

[15]  S. Jadhav,et al.  Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[16]  A. Christopoulos,et al.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.